Publications

Recent years have seen acquisitions become a common element of any growth strategy for multinationals engaged in China's pharmaceutical market.  At least half of the top 10 multinationals in China appear to be actively pursuing one or more targets with the main areas of therapeutic interest being the so-called "Western diseases" of diabetes, cancer, heart disease, etc.  There is also a keen interest in the biotech sector but as yet relatively little M&A activity in this space.  Some companies continue to pursue targets in the pharmaceutical distribution sector although compliance problems are often insurmountable.

Download Full Report